HLB Genex, Inc. (KOSDAQ:187420)

Market Cap	93.96B
Revenue (ttm)	39.01B
Net Income (ttm)	-18.57B
Shares Out	29.14M
EPS (ttm)	-739.83
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	46,448
Average Volume	42,120
Open	3,180.00
Previous Close	3,175.00
Day's Range	3,145.00 - 3,230.00
52-Week Range	2,880.00 - 5,930.00
Beta	0.10
RSI	46.39
Earnings Date	Aug 12, 2025

About HLB Genex

HLB Genex, Inc. engages in the research and development, production, import/export, and sale of enzymes and fermentation products in South Korea and internationally. Its industrial special enzyme products include lactase; catalase for use in semiconductor industry; and proteinase K for molecular diagnostics and genetic engineering experiments, as well as bio-health care ingredients comprise N-phytosphingosine and vitamin K2. The company also develops drug candidates for wet and dry macular degeneration, inflammatory bowel disease, anticancer, o...

• Industry: Industrial Organic Chemicals
• Founded: 2000
• Employees: 79
• Stock Exchange: KOSDAQ
• Ticker Symbol: 187420

Financial Performance

In 2024, HLB Genex's revenue was 35.43 billion, an increase of 31.18% compared to the previous year's 27.01 billion. Losses were -18.83 billion, 538.2% more than in 2023.